View in EDS

Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with sickle cell disease.

Saved in:
Bibliographic Details
Title: Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with sickle cell disease.
Authors: Alasbali R; Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia., Alzahrani M; Department of Hematology/Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Wilkerson K; Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA., Akhom P; Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA., Alotaibi F; Department of Research, KFSHRC - Riyadh, Riyadh, Saudi Arabia., Alahmari B; Department of Hematology/Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., de la Fuente J; Department of Pediatrics, St. Mary's Hospital, Imperial College, London, UK., DeBaun MR; Department of Pediatrics, Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, Vanderbilt University School of Medicine, Nashville, TN, USA., Rasheed W; Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia., Samarkandi H; Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia.; Pharmaceutical Care Division, KFSHRC, Riyadh, Saudi Arabia., El Fakih R; Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia., Saleh M; Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia., Elhassan T; Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia., Alzahrani H; Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia., Aljurf M; Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia., Almohareb F; Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia., Kassim AA; Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA., AlAhmari A; Department of Hematology, Stem Cell Transplant & Cellular Therapy, Cancer Centre of Excellence, KFSHRC - Riyadh, Riyadh, Saudi Arabia. aalahmari7@kfshrc.edu.sa.
Source: Bone marrow transplantation [Bone Marrow Transplant] 2026 Jul; Vol. 61 (7), pp. 847-851. Date of Electronic Publication: 2026 Apr 28.
Publication Type: Journal Article; Multicenter Study; Clinical Trial
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5365
DOI:10.1038/s41409-026-02876-3